
Nicox's Extraordinary Shareholder Meeting

May 17, 2017
Sophia Antipolis, France

Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, informs its shareholders that the ordinary shareholder meeting was held on May 16, 2017 and all resolutions were approved. The extraordinary shareholder meeting convened on first call could not be held as the quorum required by law was not reached.

The shareholders thus are convened on second call for an Extraordinary shareholder meeting on same agenda on **Tuesday May 30, 2017** at 2:00 pm CET in the offices of Drakkar D - BuroClub - room Colomb - 2405 route des Dolines - 06560 Valbonne Sophia Antipolis – France.

The documents mentioned in articles R.225-73-1 of the French Code de commerce, including those to be presented at the shareholder meeting, are available on the Company's website www.nicox.com. These documents are also available to shareholders at the headquarters of the Company.

Shareholders may vote by proxy, by internet or by attending the shareholder meeting in person. A guide explaining how to vote, and notably how to vote by internet, is available on Nicox's website. Shareholders may also contact the Company's Investor Relations team at Age2017@nicox.com for any question on the voting process.

About Nicox

Nicox is an international ophthalmic R&D company utilizing innovative science to maintain vision and improve ocular health. By leveraging its proprietary expertise in nitric oxide donation and other technologies, the Company is developing an extensive portfolio of novel therapies that target multiple ophthalmic conditions, including glaucoma. Nicox currently has two products at the pre-approval stage with the U.S. Food and Drug Administration (FDA) and a promising pipeline including next-generation stand-alone nitric-oxide donors, with the potential to treat a range of ophthalmic indications. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com.

Analyst coverage

Bryan, Garnier & Co	Hugo Solvet	Paris, France
Invest Securities	Martial Descoutures	Paris, France
Gilbert Dupont	Damien Choplain	Paris, France
Stifel	Christian Glennie	London, UK



Contacts

Nicox
Investor Relations Department
T +33 (0)4 97 24 53 00
communications@nicox.com

Disclaimer

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.



Nicox S.A.

Drakkar 2
Bât D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99